xerxer, from a clinical perspective, there is a lot to be...

xerxer, from a clinical perspective, there is a lot to be interested in. However, as an investor we can't escape the fact that the coy has virtually no cash left. Unless they can strike a good cash flow deal pretty soon, as others have pointed out, they will need a CR. I would think the next CR would have to be a pretty big one too as their really is no decent revenue stream in the near term.
I can't help think that a CR around the current share price is not worth it. The NTA was at the last report at @4C, and not much change has occurred value wise. I would only re-enter with a decent announcement that provided definate revenue and a SP around 3-6c.